ReviewBiomarker research2026
Radiogenomic landscape of the hallmarks of cancer.
Review in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiogenomics, by integrating medical imaging and multidimensional genomic data, aims to identify non-invasive imaging biomarkers to aid in deciphering the molecular characteristics of tumors and provide potential support for precision medicine. However, existing research is primarily limited to statistical associations between imaging phenotypes and genes, lacking an explanation of the underlying biological mechanisms behind imaging features. This limitation severely restricts its clinical translation and application. The “hallmarks of cancer” theory proposed by Hanahan and Weinberg provides a core framework for systematically understanding tumor biological behavior. This review, for the first time, systematically associates and interprets radiogenomics with all cancer hallmarks and enabling characteristics, aiming to bridge the gap between imaging phenotypes and tumor biological mechanisms, enhance the biological interpretability of radiogenomics, and promote its advancement towards mechanism-driven precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.